Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (새로운 창 열기)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexed‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (새로운 창 열기)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (새로운 창 열기)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Source‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indexed‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (새로운 창 열기)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (새로운 창 열기)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indexed‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (새로운 창 열기)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (새로운 창 열기)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Source‎: Blood 2003;102(4):1529-30.

Indexed‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (새로운 창 열기)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (새로운 창 열기)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Source‎: Transfusion 2007;47(10):1830-6.

Indexed‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (새로운 창 열기)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (새로운 창 열기)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Source‎: Iran J Blood Cancer 2009;1(4):147-50.

Indexed‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (새로운 창 열기)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (새로운 창 열기)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Source‎: Int J Hematol 2012;95(1):51-6.

Indexed‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (새로운 창 열기)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (새로운 창 열기)

Perrine SP.

Source‎: Pediatr Ann 2008;37(5):339-46.

Indexed‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (새로운 창 열기)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (새로운 창 열기)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Source‎: Sci Rep. 2022;12(1):2752.

Indexed‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (새로운 창 열기)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (새로운 창 열기)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Source‎: Haematologica 2004;89(10):1172-8.

Indexed‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (새로운 창 열기)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (새로운 창 열기)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Source‎: Arch Iran Med 2009;12(3):295-7.

Indexed‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (새로운 창 열기)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (새로운 창 열기)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Source‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indexed‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (새로운 창 열기)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (새로운 창 열기)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Source‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indexed‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (새로운 창 열기)

Fetal globin gene inducers: novel agents and new potential. (새로운 창 열기)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Source‎: Ann N Y Acad Sci 2010;1202:158-64.

Indexed‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (새로운 창 열기)